哈洛泽生物

最新新闻

• 评级变动
  Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $75
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 公司公告
  Halo Xin.com: Prompt Announcement on Disclosing the Report for the Third Quarter of 2023
  SZSI · 2023/10/24
• 评级变动
  China Resources Land Life (1209.HK): A leading operator of consumer‑focused HALO assets in China.
  Huatai Securities · 2026/5/15
• H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $115
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Analysts' Top NA Picks: High Roller Technologies, Inc. (ROLR), Halozyme (HALO)
  TipRanks · 2026/9/3
• 评级变动
  H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $95
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• Halozyme Therapeutics(HALO.US) Officer Sells US$6.61 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/10/9
• 公司公告
  Halo Technologies Holdings Ltd: HALO to issue Convertible Notes to raise up to AUD6.75m
  N/A · 2024/8/29
• Leerink Partners Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $110
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 公司公告
  Better Choice Co | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-HEP Partners LLC(7.5%),HH-Halo GP LLC(7.5%), etc.
  SEC · 2024/2/15
• 评级变动
  J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)
  TipRanks · 2026/5/20
• 公司公告
  Akanda | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Halo Collective Inc.(0%)
  SEC · 2024/2/21
• Another claim for RMB 23.45 million! Halo Microelectronics faces further arbitration claims from a former employee. Two litigation and arbitration cases disclosed within the past month involve total claims exceeding RMB 70 million.
  Gelonghui Finance · 2026/10/10
• Form 144 | Halozyme Therapeutics(HALO.US) Director Proposes to Sell 3.64 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• 公司公告
  RIMBACO: JOINT ANNOUNCEMENT1. CLOSE OF MANDATORY UNCONDITIONAL CASH OFFER BY CMB INTERNATIONAL CAPITAL LIMITED AND CEB INTERNATIONAL CAPITAL CORPORATION LIMITED FOR AND ON BEHALF OF AUREOLE HALO LIMITED TO ACQUIRE ALL THE ISSUED SHARES OF RIMBACO GROUP GLOBAL LIMIT
  HKEX · 2026/7/7
• 评级变动
  Goldman Sachs Maintains Halozyme Therapeutics(HALO.US) With Sell Rating, Raises Target Price to $57
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $66.41
  \u5e02\u573a\u8d44\u8baf · 2026/5/12
• 评级变动
  Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $93
  \u5e02\u573a\u8d44\u8baf · 2026/5/12
• 评级变动
  A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $93 to $115
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $93
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• Halozyme Therapeutics(HALO.US) Officer Sells US$6.28 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 评级变动
  TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $96
  \u5e02\u573a\u8d44\u8baf · 2026/5/12
• H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $115
  \u5e02\u573a\u8d44\u8baf · 2026/9/3
• Halozyme Therapeutics(HALO.US) Officer Sells US$6.44 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/12

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。